DSID,AU,TI,JR,PY,VL,IS,PG,AB,SA,REGID,STD.IND,STD.DESIGN,STD.GEO.LOCATION,STD.PHASE,ARM.NUM,ARM.BLIND,ARM.RANDFLG,ARM.TRT,ARM.TRTCLASS,ARM.DOSE,ARM.DOSEU,ARM.ROUTE,ARM.REGIMEN,ARM.FORMULATION,N.STUDY,N.ARM,N.ARM.STATANAL,N.ARM.EVENT.SUBJ,STATANAL.POP,STATANAL.METHOD,STATANAL.IMP.METHOD,ARM.TIME1,ARM.TIME1U,ENDPOINT,BSL.STAT,BSL.VAL,BSL.VALU,BSL.VAR,BSL.VARU,BSL.LCI,BSL.UCI,CHBSL.STAT,CHBSL.VAL,CHBSL.VALU,CHBSL.VAR,CHBSL.VARU,CHBSL.LCI,CHBSL.UCI,RSP.STAT,RSP.VAL,RSP.VALU,RSP.VAR,RSP.VARU,RSP.LCI,RSP.UCI,PCHBSL.STAT,PCHBSL.VAL,PCHBSL.VAR,PCHBSL.VARU,PCHBSL.LCI,PCHBSL.UCI,ARM.PCT.MALE,ARM.AGE,ARM.AGEU
705,Roden M; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC,"Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial",CARDIOVASC.DIABETOL,2015,14,154.0,1~11,,EMPA-REG Mono,NCT01177813;NCT01289990,T2D,Parallel,BE;CA;CN;DE;IN;IE;JP;CH;US,Phase 3,0.0,Double-Blind Extension,True,placebo,Placebo,0,MG/DAY,ORAL,QD,TAB,899,228.0,228,,FAS,ANCOVA,LOCF,76.0,WK,HbA1c,Mean,7.91,percent,0.78,SD,,,LS Mean,0.13,percent,0.06,SE,0.012,0.248,LS Mean,8.01,percent,0.06,SE,7.892,8.128,LS Mean,1.651,,,,,53.9,54.9,YR
705,Roden M; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC,"Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial",CARDIOVASC.DIABETOL,2015,14,154.0,1~11,,EMPA-REG Mono,NCT01177813;NCT01289990,T2D,Parallel,BE;CA;CN;DE;IN;IE;JP;CH;US,Phase 3,1.0,Double-Blind Extension,True,empagliflozin,SGLT2,10,MG/DAY,ORAL,QD,TAB,899,224.0,224,,FAS,ANCOVA,LOCF,76.0,WK,HbA1c,Mean,7.87,percent,0.88,SD,,,LS Mean,-0.65,percent,0.06,SE,-0.768,-0.532,LS Mean,7.22,percent,0.06,SE,7.102,7.338,LS Mean,-8.256,,,,,63.4,56.2,YR
705,Roden M; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC,"Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial",CARDIOVASC.DIABETOL,2015,14,154.0,1~11,,EMPA-REG Mono,NCT01177813;NCT01289990,T2D,Parallel,BE;CA;CN;DE;IN;IE;JP;CH;US,Phase 3,2.0,Double-Blind Extension,True,empagliflozin,SGLT2,25,MG/DAY,ORAL,QD,TAB,899,224.0,224,,FAS,ANCOVA,LOCF,76.0,WK,HbA1c,Mean,7.86,percent,0.85,SD,,,LS Mean,-0.76,percent,0.06,SE,-0.878,-0.642,LS Mean,7.12,percent,0.06,SE,7.002,7.238,LS Mean,-9.654,,,,,64.7,53.8,YR
705,Roden M; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC,"Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial",CARDIOVASC.DIABETOL,2015,14,154.0,1~11,,EMPA-REG Mono,NCT01177813;NCT01289990,T2D,Parallel,BE;CA;CN;DE;IN;IE;JP;CH;US,Phase 3,3.0,Double-Blind Extension,True,sitagliptin,DPP4,100,MG/DAY,ORAL,QD,TAB,899,223.0,223,,FAS,ANCOVA,LOCF,76.0,WK,HbA1c,Mean,7.85,percent,0.79,SD,,,LS Mean,-0.53,percent,0.06,SE,-0.648,-0.412,LS Mean,7.34,percent,0.06,SE,7.222,7.458,LS Mean,-6.732,,,,,63.2,55.1,YR
